Wide Ranks

AVDL

Avadel Pharmaceuticals plc

11.17

Top Statistics
Market Cap 1 B Forward PE 21.08 Revenue Growth 613.20 %
Current Ratio 2.97 Trailing PE 0.0000 Earnings Growth 0.00 %
Profit Margins -52.53 % Peg Ratio Dividend Yield 0.00 %
Enterprice / EBITA -16.91 Enterprise / Revenue 7.59 Price To Sales Trailing12 Months 7.79
Profitability
Profit Margins -52.53 % Operating Margins -0.65 %
Balance Sheet
Total Cash 65 M Total Cash Per Share 0.6830 Total Debt 38 M
Total Debt To Equity 51.24 Current Ratio 2.97 Book Value Per Share 0.7750
All Measures
Short Ratio 621.00 % Message Board Id finmb_28567 Shares Short Prior Month 10 M
Return On Equity -0.7854 City Dublin Uuid eed4625d-e4bb-3438-b887-c6091808e157
Previous Close 11.15 First Trade Date Epoch Utc 834 M Book Value 0.7750
Total Debt 38 M Volume 712763 Price To Book 14.41
Fifty Two Week Low 10.41 Total Cash Per Share 0.6830 Total Revenue 138 M
Shares Short Previous Month Date 1 B Target Median Price 22.50 Audit Risk 9
Max Age 86400 Recommendation Mean 1.30 Sand P52 Week Change 0.3133
Operating Margins -0.65 % Target Mean Price 23.60 Net Income To Common -72575000
Short Percent Of Float 0.1046 Implied Shares Outstanding 96 M Trailing Peg Ratio None
Last Fiscal Year End 1 B Average Daily Volume10 Day 1 M Average Volume10days 1 M
Total Cash 65 M Next Fiscal Year End 1 B Revenue Per Share 1.48
Held Percent Insiders 0.0477 Ebitda Margins -44.88 % Trailing PE 0.0000
Date Short Interest 1 B Most Recent Quarter 1 B Share Holder Rights Risk 3
Regular Market Previous Close 11.15 Target Low Price 20.00 Gmt Off Set Milliseconds -18000000
Fifty Day Average 13.04 Open 11.21 Free Cashflow -58922500
Dividend Yield 0.00 % Return On Assets -0.2214 Time Zone Short Name EST
Board Risk 4 Trailing Eps -0.7500 Day Low 11.00
Address1 10 Earlsfort Terrace Shares Outstanding 96 M Compensation Risk 6
Price Hint 2 Target High Price 30.00 Website https://www.avadel.com
52 Week Change -0.0321 Average Volume 1 M Forward Eps 0.6800
Recommendation Key strong_buy Compensation As Of Epoch Date 1 B Quick Ratio 240.50 %
Is_sp_500 False Regular Market Day High 11.32 Profit Margins -52.53 %
Debt To Equity 51.24 Fifty Two Week High 19.09 Day High 11.32
Shares Short 8 M Regular Market Open 11.21 Industry Key drug-manufacturers-specialty-generic
Earnings Growth 0.00 % Enterprise To Revenue 7.59 Revenue Growth 613.20 %
Shares Percent Shares Out 0.0915 Operating Cashflow -82809000 Currency USD
Time Zone Full Name America/New_York Market Cap 1 B Is_nasdaq_100 False
Zip 2 Quote Type EQUITY Industry Drug Manufacturers - Specialty & Generic
Long Name Avadel Pharmaceuticals plc Overall Risk 4 Regular Market Day Low 11.00
Held Percent Institutions 0.8007 Current Price 11.17 Enterprise To Ebitda -16.91
Financial Currency USD Current Ratio 2.97 Gross Margins 91.92 %
Industry Disp Drug Manufacturers - Specialty & Generic Number Of Analyst Opinions 10 Country Ireland
Float Shares 83 M Two Hundred Day Average 15.09 Governance Epoch Date 1 B
Enterprise Value 1 B Price To Sales Trailing12 Months 7.79 Forward PE 21.08
Regular Market Volume 712763 Ebitda -62007000 Exchange NGM
Go to Yahoo Finance Go to Seeking Alpha 
Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States.

Its lead product candidate is LUMRYZ, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness or cataplexy in adults with narcolepsy.

The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017.

Avadel Pharmaceuticals plc was incorporated in 2015 and is headquartered in Dublin, Ireland.